Martin Glas

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial

Ulrich Herrlinger, Theophilos Tzaridis, Frederic Mack et al. · The Lancet · 2019 · 556 citations · Full text

Hematological Malignancy, Neuro-oncology, Treatment Strategies +13

c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype

Yun-Qing Li, Angela Li, Martin Glas et al. · Proceedings of the National Academy of Sciences · 2011 · 259 citations · Full text

Stem Cell Biology, Cancer Biology, Glioma +21

Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O⁶-Methylguanine–DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial

Ulrich Herrlinger, Niklas Schäfer, Astrid Weyerbrock et al. · Journal of Clinical Oncology · 2016 · 194 citations

Endothelial cell‐derived angiopoietin‐2 is a therapeutic target in treatment‐naive and bevacizumab‐resistant glioblastoma

Alexander Scholz, Patrick N. Harter, Sebastian Cremer et al. · EMBO Molecular Medicine · 2015 · 167 citations · Full text

Anticancer Effects of Niclosamide in Human Glioblastoma

Anja Wieland, Daniel Trageser, Sabine Gogolok et al. · Clinical Cancer Research · 2013 · 159 citations